United Therapeutics price target raised to $75 from $65 at Argus Argus increased its price target on United Therapeutics after the company reported higher than expected Q4 EPS. The firm continues to believe that the company will generate strong long-term growth, and it maintains a Buy rating.
News For UTHR From The Last 14 Days
Check below for free stories on UTHR the last two weeks.
United Therapeutics jumps after court rules generic will infringe United Therapeutics (UTHR) alleged patent infringement against Sandoz, a unit of Novartis (NVS), related to the latter's filing for approval of a generic version of United Therapeutics' remodulin drug. A New Jersey court ruled today that Sandoz's proposed ANDA product will infringe the claims of UTC's '117 patent, according to a court filing. Following the court ruling, shares of United Therapeutics are up 15% to $105.39 in morning trading.